Cargando…

Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway

Gemcitabine is the first-line chemotherapeutic agent for pancreatic cancer. However, gemcitabine-resistance frequently leads to poor prognosis. Exploring new chemotherapeutic agents is important for patients with gemcitabine-resistant pancreatic cancer. In this study, we established a new acquired g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weng, Wanwen, Hong, Jiawei, Owusu-Ansah, Kwabena G., Chen, Bingjie, Zheng, Shusen, Jiang, Donghai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761725/ https://www.ncbi.nlm.nih.gov/pubmed/36544829 http://dx.doi.org/10.1016/j.heliyon.2022.e12064

Ejemplares similares

COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer
por: Owusu-Ansah, Kwabena Gyabaah, et al.
Publicado: (2019)

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
por: Alain, Tommy, et al.
Publicado: (2012)

Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis
por: Bobiński, Marcin, et al.
Publicado: (2020)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
por: Silic-Benussi, Micol, et al.
Publicado: (2023)

Targeting mTOR dependency in pancreatic cancer
por: Morran, Douglas C, et al.
Publicado: (2014)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance
por: Duluc, Camille, et al.
Publicado: (2015)

Pralatrexate for refractory mycosis fungoides in two Japanese patients
por: Teraishi, Mika, et al.
Publicado: (2021)

Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1
por: Wang, Jun, et al.
Publicado: (2017)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

NKILA, a prognostic indicator, inhibits tumor metastasis by suppressing NF-κB/Slug mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Chen, Ronggao, et al.
Publicado: (2020)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling
por: Cui, Jing, et al.
Publicado: (2021)

Inhibition of TRIM32 by ibr‐7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway
por: Zhang, Bo, et al.
Publicado: (2021)

Aspirin increases the efficacy of gemcitabine in pancreatic cancer by modulating the PI3K/AKT/mTOR signaling pathway and reversing epithelial‑mesenchymal transition
por: Zhou, Hanyu, et al.
Publicado: (2023)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
por: Ducker, Gregory S., et al.
Publicado: (2013)

Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer
por: Lv, Tangfeng, et al.
Publicado: (2015)

Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Sensitivity of Global Translation to mTOR Inhibition in REN Cells Depends on the Equilibrium between eIF4E and 4E-BP1
por: Grosso, Stefano, et al.
Publicado: (2011)

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
por: Casanova, M, et al.
Publicado: (2011)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

Periplocin Induces Apoptosis of Pancreatic Cancer Cells through Autophagy via the AMPK/mTOR Pathway
por: Zhang, Hewei, et al.
Publicado: (2022)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Role of nutrients and mTOR signaling in the regulation of pancreatic progenitors development
por: Elghazi, Lynda, et al.
Publicado: (2017)

Luteolin, a natural flavonoid, inhibits methylglyoxal induced apoptosis via the mTOR/4E-BP1 signaling pathway
por: Liu, Yi, et al.
Publicado: (2017)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
por: Lin, Gigin, et al.
Publicado: (2018)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v4knhfs1de0723vtfg09vrnmd7